About

Publications While At HealthPartners

selected publications

Journal Article

Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: patient-reported outcomes in ECOG-ACRIN EA1131. 

Cancer. 2024

Financial hardship among patients with early-stage colorectal cancer. 

JAMA network open. 2024

Patient-reported financial burden of treatment for colon or rectal cancer. 

JAMA network open. 2024

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL. 

Blood. 2024

Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. 

Journal of Clinical Oncology. 2021

Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. 

Cancer medicine. 2020

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. 

Journal of Clinical Oncology. 2020

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study. 

Journal of Clinical Oncology. 2019

E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. 

Journal of Clinical Oncology. 2017

Contact

full name

L. I. Wagner

Quick Info

 

Collaboration

Co-author network

Map of science